Large Skin Ulcer Due to a Subcutaneous Orthopaedic Implant After Bevacizumab Therapy: A Case Report.

CASE: Bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor that is involved in the inhibition of vasculogenesis and angiogenesis. We report the case of a patient who developed a severe skin ulcer at the site of the surgical incision 5 years after clavicular fracture fixation with a titanium plate. This ulcer represents an adverse event of bevacizumab therapy for sigmoid colon cancer.

CONCLUSION

Bevacizumab therapy is widely used, particularly for the treatment of metastatic colon cancer and other solid tumors, although it is associated with several adverse events, including delayed wound-healing and skin ulcers. However, to our knowledge, orthopaedic-related adverse events have not previously been reported.